Biofield Therapy in Oncology: Modulation of Tumor Biology in Pancreatic and Liver Cancer

Biofield Therapy in Oncology: Modulation of Tumor Biology in Pancreatic and Liver Cancer


  • Confirmatory research and advancement of prior biofield therapy research in cancers with the highest rate of mortality, examining the relevant biological mechanisms of action through multidimensional monitoring, rigorous treatment/sham/control conditions, dosage modulation, blockage of biofield signal, and exploratory distance therapy


  • Cancer cell mortality increases and proliferation decreases with biofield therapy relative to control and sham groups invitro and invivo in a way that is detectable not only through tumor remission/reduction but also by various biological markers


  • Biofield therapy is able to put cancer cells into senescence, having demonstrated antitumor and anti-metastatic effects in human and mouse pancreatic cancer, decreasing cell growth and metabolism in cell culture invitro
  • Biofield therapy blocks cancer cell cycle progression in G0/G1 and G2/M stages in human and mouse pancreatic cancer cells
  • Biofield therapy inhibits tumor growth invivo, especially liver metastasis, in a Panc-1 pancreatic mouse orthotopic model
  • Biofield therapy reduces cancer cell membrane voltage potential leading to hyperpolarization in multiple cancer cell lines (vs. the well-known cancerous depolarization), which suggests the crucial role of cell membrane potential and ion channels in the proliferation and metastasis of cancer tumors
  • By way of mechanism of action, biofield therapy modifies key cell signaling proteins (proteomic expression, upregulation/downregulation) and leads to significant and specific non-genomic alterations known to interact as a system

Research abstract (journal publication is currently in process):

Presentation to the American Association for Cancer Research April 2022